Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/21/2013

Company Name Symbol %Change
VIPSHOP HOLD VIPS
6.11%
FEDERAL MOGU FDML
4.83%
RADIANT LOGI RLGT
4.26%
EAGLE BULK S EGLE
3.46%
ERICKSON AIR EAC
3.61%

Gentiva Modifies Credit Facility

by Zacks Equity Research

March 07, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Tuesday, Gentiva Health Services Inc. ( GTIV - Analyst Report ) announced an amendment to its senior secured credit agreement to make the financial covenants more flexible for the remaining period of the credit facility. The amendment consists of alteration of the definition of consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) in the credit agreement.

Consequently, all expenses related to Gentiva’s cost realignment initiative, certain non-recurring cash charges and legal settlements will be added back during the calculation of consolidated EBITDA. Additionally, the maximum limit for the consolidated leverage ratio has been raised to 6.25:1.00 for the period from January 2012 to September 2014 and 5.75:1.00 subsequently. The previous limit was 4.50:1.00 till September 2012, 3.75:1.00 from October 2012 to September 2013 and 3.00:1.00 beyond that.

Further, the minimum interest coverage ratio requirement has been relaxed to 2.00:1.00 for the period from January 2012 to June 2013, 1.75:1.00 from July 2013 to June 2014 and 2.00:1.00 from July 2014 onwards. Moreover, the definition of consolidated interest charges has been modified to exclude non-cash interest charges, which were previously included.

The amendment also hiked the interest rates on the term loans taken under the credit facility by 1.75% per annum. Thus, the new rates applicable on the Eurodollar term loans A and B are 6.25% and 6.50%, respectively.

Additionally, Gentiva is now allowed to make discounted prepayments of outstanding term loans through a Dutch auction process. However, the company will have to pay various fees relating to the amendment, one of them being a consent fee of about 0.50% of term loans and revolving credit obligations under the credit agreement. This consent fee will be paid to all lenders who give their consent to the amendment.

Gentiva also repaid $50 million of its principal outstanding under term loans A and B on a pro rata basis and downsized its revolving credit facility to $110 million from $125 million. The company is implementing a two-pronged strategy to increase the flexibility of its financial covenants over the next few years in an effort to better reflect the changed reimbursement environment. The amendment of the credit facility is the second part of the strategy.

Gentiva is a leading national provider of comprehensive home health services and competes with organizations like Amedisys Inc. ( AMED - Snapshot Report ) and Lincare Holdings Inc. ( ) .

Shares of Gentiva currently carry a Zacks #2 Rank, implying a short-term Buy rating. Considering the fundamentals, we maintain our long-term Neutral recommendation on the shares.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.